Comparing Recovery After Transcatheter Aortic Valve Replacement Using Different Sedation Medicines A Study of Propofol, Dexmedetomidine, and Midazolam with Fentanyl Sedation

What this Trial Is About

This clinical trial is investigating whether different sedation medications used during transcatheter aortic valve replacement TAVR affect patients recovery quality. The main focus is to compare three sedation regimenspropofol, dexmedetomidine, and midazolam with fentanyland assess how they influence recovery on the first day after the procedure. The study aims to understand which sedation approach may lead to better postoperative outcomes in adults undergoing TAVR. Participants will be randomly assigned to receive one of the three sedation medications during their TAVR procedure. Propofol will be given intravenously at doses titrated to effect, dexmedetomidine will be administered via infusion adjusted similarly, and a combination of midazolam and fentanyl will be used to achieve sedation and pain relief. The sedation is administered during the procedure under monitored anesthesia care. Throughout the study, participants will complete surveys about their pain levels, overall recovery experience, and satisfaction with anesthesia on postoperative days 1 and 7. Researchers will also monitor heart rate changes, length of hospital stay, postoperative delirium, incidence of complications, and other recovery-related outcomes up to 30 days after the procedure. This allows comprehensive assessment of recovery quality and safety following different sedation methods.

Patient Quality of Recovery After TAVR With Different Sedation Regimens